Myeloid Therapeutics has a total of 187 patents globally, out of which 18 have been granted. Of these 187 patents, more than 85% patents are active. The United States of America is where Myeloid Therapeutics has filed the maximum number of patents, followed by Australia and Europe (EPO). Parallelly, United States of America seems to be the main focused R&D centre and also is the origin country of Myeloid Therapeutics.
Myeloid Therapeutics was founded in 2019. The company is developing a cell therapy platform that reprograms innate immune cells, especially myeloid cells, to identify and eliminate harmful or cancerous cells. This approach overcomes key limitations of existing therapies and enables more effective disease treatment by using versatile immune responses.
Do read about some of the most popular patents of Myeloid Therapeutics which have been covered by us in this article and also you can find Myeloid Therapeutics patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Myeloid Therapeutics patent portfolio.
How many patents does Myeloid Therapeutics have?
Myeloid Therapeutics has a total of 187 patents globally. These patents belong to 26 unique patent families. Out of 187 patents, 160 patents are active.
How Many Patents did Myeloid Therapeutics File Every Year?
Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.
| Year of Patents Filing or Grant | Myeloid Therapeutics Applications Filed | Myeloid Therapeutics Patents Granted |
| 2025 | 4 | 3 |
| 2024 | 15 | 9 |
| 2023 | 35 | 2 |
| 2022 | 54 | 1 |
| 2021 | 25 | 3 |
| 2020 | 53 | – |
| 2016 | 1 | – |
How many Myeloid Therapeutics patents are Alive/Dead?
Worldwide Patents
How Many Patents did Myeloid Therapeutics File in Different Countries?
Countries in which Myeloid Therapeutics Filed Patents
| Country | Patents |
| United States of America | 40 |
| Australia | 12 |
| Europe (EPO) | 11 |
| United Kingdom | 11 |
| Hong Kong (S.A.R.) | 11 |
| Canada | 10 |
| Singapore | 9 |
| Israel | 9 |
| China | 8 |
| Japan | 8 |
| South Africa | 7 |
| India | 7 |
| Mexico | 7 |
| Brazil | 7 |
| Korea (South) | 7 |
Where are Research Centers of Myeloid Therapeutics Patents Located?
10 Best Myeloid Therapeutics Patents
US20170151281A1 is the most popular patent in the Myeloid Therapeutics portfolio. It has received 60 citations so far from companies like ST Phi Therapeutics, Carisma Therapeutics, Torque Therapeutics.
Below is the list of 10 most cited patents of Myeloid Therapeutics:
| Publication Number | Citation Count |
| US20170151281A1 | 60 |
| WO2020223550A1 | 25 |
| US10980836B1 | 14 |
| WO2021119538A1 | 9 |
| US11517589B2 | 8 |
| US20210252053A1 | 8 |
| US20220001031A1 | 7 |
| US11918605B1 | 6 |
| US20220202856A1 | 6 |
| US20220175831A1 | 6 |
What Percentage of Myeloid Therapeutics US Patent Applications were Granted?
Myeloid Therapeutics (Excluding its subsidiaries) has filed 38 patent applications at USPTO so far (Excluding Design and PCT applications). Out of these 10 have been granted leading to a grant rate of 62.5%.
Below are the key stats of Myeloid Therapeutics patent prosecution at the USPTO.
Which Law Firms are managing US Patents for Myeloid Therapeutics?
| Law Firm | Total Applications | Success Rate |
| Myeloid Therapeutics Inc | 33 | 63.64% |
| Wilson Sonsini Goodrich & Rosati | 4 | 75% |
| Oliff Plc | 1 | 0% |
What are Myeloid Therapeutics key innovation segments?
What Technologies are Covered by Myeloid Therapeutics?
The chart below distributes patents filed by Myeloid Therapeutics in different countries on the basis of the technology protected in patents. It also represents the markets where Myeloid Therapeutics thinks it’s important to protect particular technological inventions.
R&D Focus: How has Myeloid Therapeutics search focus changed over the years?
EXCLUSIVE INSIGHTS COMING SOON!
Interested in knowing about the areas of innovation that are being protected by Myeloid Therapeutics?
